Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

about

Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

Item

http://www.wikidata.org/entity/Q38823374

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

@en

type

Item

label

Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

@en

prefLabel

Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

@en

P1476

Evolving treatments for advanced gastric cancer: appraisal of the survival trend.

@en

P2093

Adriana Romiti

http://www.w3.org/2001/XMLSchema#string

Concetta Elisa Onesti

http://www.w3.org/2001/XMLSchema#string

Michela Roberto

http://www.w3.org/2001/XMLSchema#string

Rosa Falcone

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Cancer statistics, 2013

Comprehensive molecular characterization of gastric adenocarcinoma

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

P304

717-729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14737140.2016.1184979

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Angelo Zullo

Paolo Marchetti

P577

2016-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27137418

http://www.w3.org/2001/XMLSchema#string